智慧芽：2022中美口服新冠药对比&全球3CL抑制剂专利分析报告（69页）.pdf

上传人：小**

文档编号：88987

上传时间：2022-08-05

格式：PDF

页数：69

大小：4.24MB

文档加载中……请稍候！
如果长时间未打开，您也可以点击刷新试试。

下载文档到电脑，查找使用更方便

VIP专享文档

下载	加入VIP,免费下载

版权申诉 word格式文档无特别注明外均可编辑修改；预览文档经过压缩，下载后原文更清晰！ 立即下载

配套讲稿：: 如PPT文件的首页显示word图标，表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
特殊限制：: 部分文档作品中含有的国旗、国徽等图片，仅作为作品整体效果示例展示，禁止商用。设计者仅对作品中独创性部分享有著作权。
关键词：: 智慧 2022 中美口服新冠药对比全球 CL 抑制剂专利分析报告 69

资源描述：: 《智慧芽：2022中美口服新冠药对比&全球3CL抑制剂专利分析报告（69页）.pdf》由会员分享，可在线阅读，更多相关《智慧芽：2022中美口服新冠药对比&全球3CL抑制剂专利分析报告（69页）.pdf（69页珍藏版）》请在三个皮匠报告文库上搜索。

1、!#$%&()*+,-*(./0+1.*23(4(546.2780!?!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$!#$%&()*!%&()!%!%#*+,-&./01!%!#!+*,-./012345*6!#%*+23456&7!%!$!#%#*+23489:;!6*,78-7/09:;123$&*=!$%!*?56ABCD89)!%!E!$%#!+?56ABCD89*?;!S*6AB!#CDETUVW*!X!G%HIJKLM$NO!#PQRST!%!U!G%VW$NO!#PQR!

2、%!E!G%#XVW$NO!#PQR!%!#!G%#YZ$NO!#PQRIJ!%!$F!G%#%2_Sa$NO!#PQRabcIJ!%!$F!#$%&()*+,-.!#$#/01()*+,-$!G%#%#d_SaIJ)!%!$#!#$2345,-#!#67289:;!#-67289?ABC9DE=(),-F!#G 67289HIJKLMNDE OPOQ,-R!#!,STUVWX,YZXZWWX,-R!#F,T_T,STUaTWb_ZTcX,-d!#R,eZfT,YZXZWWX,G.!#d,gbXZW,YZhTUaT,G.!#$.,iUjX_Tc,STUaT,G$!#$,eklmng,oWUTh

3、Wb_ZX,G#!#$#,pki,STUaT,G-!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!#$%&!#$#?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!$%&(!)*+,#?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$!$#!()*+,-./01!$!%&-./01!2#?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$%&-./345678#?!#$%&()*+,-*(./0+1.*23(4(

4、546.2780!?!G!?!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!U!#$%&()*+,-*(./0+1.*23(4(546.2780!?!E!%#!(23)2+,%4567-./$!?%!#%901:;347$#?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!f!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!F!?%$#&901:;347$#?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!&#!8967%(!#:;?A!?!#$%&()*+,-*(./0+1.*23(4(54

5、6.2780!?!#!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e!?)#!BCDE%(!#/F89GH!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!U!*#!%(!#:;FGF#FF$#FFe#FF#FFG#FFU#FFE#FFf#FF#F#F#F$#Fe#F#FG#FU#FE#Ff#F#F#F#F#!#

6、$%&()*+,-.FF#F$FeFFGFUFEFfFFF*?+?g?h?i?j?klmnL/012#$%&()*34!#$%&()*+,-*(./0+1.*23(4(546.2780!?!E!#!$%&!#$%?XVWo!Efo!GEpVWo!e#o!$#p567856#$%9:;&()*e#FF#F#$F+?*?h?j?56#$%9:;&()*134?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!f!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#F!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!?!#$

7、%&()*+,-*(./0+1.*23(4(546.2780!?!#!#(&!$%&!#$%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#$!?!#?$%&?()*?+,?-.?/01?234?5?6789?:3*?;91?234?ABCD?(E?FG4H?IJK.?!#?$%&?()*?+,?-.?/01?234?5?6789?:3*?;?ABCD?!#?$?%&?(?)*+?&,-#?./0?12?34?567?8094?:6;(?LMNAOPAQRS?ST?FG4H?IJK.?!#?$%&?()*?+,?-.?/01?234?ABCD?U?*?V?WX?Y3

8、?Z?X*?D_%?.?a?!#?$%&?6789*?:3?b?LMNAOPAQRS?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#e!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#U!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#E!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#f!?!#$%&()*+,-*(./0+1

9、.*23(4(546.2780!?!$F!&$JKLM%(!#EFGANO#!(#()*+$%&!#$%*+,-./0?!#$!#$%&%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$!?!#$#()*#$%&%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$#!?!(1()*+23/045!#$+,-.%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$e!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$

10、!?!#/0+123456#$%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$U!?!#&/0+12789:2;?ABC;56#$%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$E!?!#)DEDF%?!#!%*+,-./%012/31.43./%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$f!#5%64+47+%*8+,9+3.:713+;/%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!eF!

11、#+%012/31.43./%?!#?%:4/814.%012A8+,9+%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e!?!#$B%C23,D/7+;%*8+,9+%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e#!?!#$%=EFGH%I8.,+A.:713/%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e$!#$#%JEC%*8+,9+%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!ee!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e!?!

12、#$%&()*+,-*(./0+1.*23(4(546.2780!?!eG!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!eU!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!eE!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!ef!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!F!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!?!#$%&()*+,-*(./0+1.*23(4(5

13、46.2780!?!$!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!U!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!E!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!f!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!GF!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G#!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G$!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!Ge!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!GG!?https:/!

展开阅读全文

三个皮匠报告文库所有资源均是用户自行上传分享，仅供网友学习交流，未经上传用户书面授权，请勿作他用。

关于本文

本文标题：智慧芽：2022中美口服新冠药对比&全球3CL抑制剂专利分析报告（69页）.pdf
链接地址：https://www.sgpjbg.com/baogao/88987.html